Olaparib(also known as Lynparza, AZD-2281, AZD 2281) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. It is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways.
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.
Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.
Role of PARP inhibitors in cancer biology and therapy.
 V.J.Weston, et al, Blood, 2010, 116(22), pp 4578-4587.
 J.M.Senra, et al, Mol. Cancer Ther., 2011, 10(10), pp 1949-1958.
 Y.Yuan, et al, J. Hematol. Oncol., 2011, 4(16), pp 1-14.
 R.Plummer, Breast Cancer Res., 2011, 13(4), pp 219:1-6.